Norepinephrine biosynthetic pathway

The norepinephrine biosynthetic pathway is a multi-step enzymatic sequence responsible for the production of the catecholamine neurotransmitter noradrenaline (norepinephrine) from the precursor amino acid L-tyrosine (StatPearls, PMID: 29262044). The process begins with the hydroxylation of L-tyrosine to L-DOPA by tyrosine hydroxylase, which serves as the rate-limiting step, followed by the decarboxylation of L-DOPA to dopamine by aromatic L-amino acid decarboxylase (UniProt, P07101). Finally, dopamine is converted into noradrenaline within synaptic vesicles by the enzyme dopamine beta-hydroxylase (UniProt, P09172). This pathway is fundamental to the function of the sympathetic nervous system and the central nervous system, influencing cardiovascular stability, metabolic rate, and cognitive processes like alertness. Dysregulation of these enzymatic steps is linked to various pathologies, including hypertension, Parkinson's disease, and autonomic failure (PubMed, PMID: 15561314). Pharmacological agents target specific enzymes within this pathway to modulate catecholamine levels; for instance, metyrosine inhibits tyrosine hydroxylase to manage pheochromocytoma, while dopamine beta-hydroxylase inhibitors are investigated for treating heart failure and hypertension (PubChem, CID: 4168).

Other names

Noradrenaline synthesis pathwayCatecholamine biosynthetic pathwayNorepinephrine synthesisL-Tyrosine to Norepinephrine conversion pathway

Inhibition of specific enzymes within the biosynthetic sequence (e.g., Tyrosine hydroxylase or Dopamine beta-hydroxylase) to reduce the production of noradrenaline and its downstream physiological effects.